keyword
Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease
2050
2059
23
16906456
The University of Auckland
Auckland Bioengineering Institute
j.lawson@auckland@auckland.ac.nz
Pharmaceutical Research
Lawson
James
N
Holford
PKPD
pharmacokinetic pharmacodynamic model
D
Hermann
Lockwood
P
This component has been included to match the published paper. However in the CellML model it is a bit redundant because population statistics are not considered - at least not yet.
Note that the epsilon in this component is a random variable with a mean of 0 and a standard deviation sigma= 4 ADASC units. However in the CellML we have to represent this as a constant value - at least for now - because as yet there is no way of representing a random variable. Possible solutions to this problem are currently being discussed and will probably involve SED-ML.
2009-12-07
2006-09
W
Ewy